Mechanism of action of Erlotinib Hydrochloride Tablets

The mechanism of action of Erlotinib Hydrochloride Tablets mainly involves multiple aspects, which work together to inhibit the growth and spread of tumor cells. The following is a detailed analysis of its mechanism of action, expressed and summarized according to points:

1.EGFRTyrosine kinase inhibition:

Erlotinib hydrochloride tablets are a small molecule tyrosine kinase inhibitor that mainly inhibits the signaling pathway of the human epidermal growth factor receptor (EGFR). EGFR is expressed on the surface of normal cells and tumor cells, and its phosphorylation plays a key role in cell growth and proliferation. Erlotinib can effectively inhibit EGFR phosphorylation in cells, thereby interfering with cell signaling and leading to cell growth arrest and / or cell death.

2.Anti-tumor proliferation and anti-angiogenesis:

Erlotinib inhibits the proliferation of tumor cells by blockingEGFR tyrosine kinase activity. In addition, it can down-regulate the expression of vascular endothelial growth factor (VEGF) and reduce the proliferation of endothelial cells and the formation of new blood vessels. This effect limits the blood supply to tumor tissue, further inhibiting tumor growth.

3.Induce tumor cell apoptosis:

The drug can up-regulate the expression of pro-apoptotic genes (such as Bax) and down-regulate the expression of anti-apoptotic genes (such as Bcl-2), which helps promote apoptosis in cancer cells. This regulation of gene expression is an important component of erlotinib's antitumor activity.

4.Inhibit tumor cell migration and invasion:

Erlotinib reduces the expression levels of matrix metalloproteinases (such as MMP-9), which helps hinder the ability of tumor cells to spread from their original site to surrounding tissues. This mechanism is of great significance for preventing tumor metastasis.

5.Inhibit cancer stem cell function:

The drug can also downregulate the expression of stem cell-related markers (such asCD44v6), thereby weakening the self-renewal and proliferation capabilities of cancer stem cells. This finding suggests that erlotinib may have a potential role in preventing tumor recurrence and metastasis.